Sandoz Group (SWX:SDZ) Opens Lendava Biosimilar Facility, Is The 7% Undervaluation Still There?

Sandoz Group (SWX:SDZ) has opened a high tech biosimilar drug substance facility in Lendava, Slovenia, a move that expands its European production network and supports its long term Bio100 portfolio ambition.

Sandoz Group’s new Lendava facility lands at a moment when momentum in the shares has been building, with a 30 day share price return of 3.66% and a year to date share price gain of 23.63%. The 1 year total shareholder return of 47.51% and 3 year total shareholder return above 7x highlight how investors have already been rewarding the biosimilars expansion story.

Scan beyond Sandoz Group and compare this biosimilars story with other potential healthcare compounders in our hand picked 126 healthcare AI stocks to see how different models of drug innovation stack up.

The Lendava build pushes Sandoz Group’s biosimilar story deeper into operations, not just into headlines. Are buyers paying up for a sturdier engine, or mainly for a stronger mood around the stock as valuation stretches are tested next?

Most Popular Narrative: 7% Undervalued

Sandoz Group last closed at CHF70.74, while the most followed narrative anchors fair value at CHF76.45, which frames the Lendava investment within a broader earnings and cash flow story built on biosimilars scale and capital allocation discipline.

Regulatory streamlining and investments in advanced in house manufacturing (notably Slovenia expansion and Just Evotec acquisition) are expected to lower production costs and speed up time to market for new biosimilars, driving margin expansion and higher net earnings.

See why 41 investors see Sandoz Group as 7% undervalued.

Result: Fair Value of CHF76.45 (UNDERVALUED)

Still, pressure on generic and biosimilar pricing, along with the reliance on partners for a sizable share of Sandoz Group’s pipeline, could quickly challenge that underpriced story.

Find out about the key risks to this Sandoz Group narrative.

Another View: Sandoz Group Looks Expensive On Earnings

Look at the share price through a simple earnings lens and Sandoz Group screens very differently. The stock trades on a P/E of 56.8x, compared with 19.2x for the European pharmaceuticals sector and a fair ratio estimate of 42.2x, which points to valuation risk if expectations reset.

For investors who lean on simple multiples rather than long range narratives, that gap in the P/E and the fair ratio raises a basic question. Is Sandoz priced for more than it has yet delivered, or does the market move closer to that higher multiple if execution stays on track?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed mood around Sandoz Group has you on the fence, act quickly and review the raw numbers. To see what optimism in the model is based on, take a look at the 3 key rewards

Looking for more Sandoz Group sized ideas?

Do not stop with one ticker. Broaden your watchlist now so you are not relying on a single story when the next opportunity shows up.

• Target potential mispriced opportunities early by scanning the 185 high quality undervalued stocks, which combines quality fundamentals with discounted valuations.
• Secure more predictable payout streams by reviewing the 225 dividend fortresses, built around companies offering substantial yields with a focus on resilience.
• Prioritise capital protection first by checking the 225 resilient stocks with low risk scores, highlighting businesses with sturdier risk profiles and stronger financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com